RhumbLine Advisers’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $573K | Sell |
83,250
-5,743
| -6% | -$39.5K | ﹤0.01% | 2599 |
|
|
2025
Q1 | $256K | Buy |
88,993
+386
| +0.4% | +$1.11K | ﹤0.01% | 2980 |
|
|
2024
Q4 | $416K | Buy |
88,607
+1,399
| +2% | +$6.58K | ﹤0.01% | 2782 |
|
|
2024
Q3 | $311K | Sell |
87,208
-4,224
| -5% | -$15.1K | ﹤0.01% | 3002 |
|
|
2024
Q2 | $567K | Buy |
91,432
+89,775
| +5,418% | +$557K | ﹤0.01% | 2582 |
|
|
2024
Q1 | $15.6K | Hold |
1,657
| – | – | ﹤0.01% | 3799 |
|
|
2023
Q4 | $11.2K | Hold |
1,657
| – | – | ﹤0.01% | 3849 |
|
|
2023
Q3 | $7.36K | Sell |
1,657
-3,134
| -65% | -$13.9K | ﹤0.01% | 3922 |
|
|
2023
Q2 | $15.8K | Sell |
4,791
-70,716
| -94% | -$233K | ﹤0.01% | 3853 |
|
|
2023
Q1 | $215K | Buy |
75,507
+15,777
| +26% | +$44.9K | ﹤0.01% | 2722 |
|
|
2022
Q4 | $435K | Buy |
59,730
+9,003
| +18% | +$65.6K | ﹤0.01% | 2532 |
|
|
2022
Q3 | $410K | Buy |
50,727
+3,200
| +7% | +$25.9K | ﹤0.01% | 2588 |
|
|
2022
Q2 | $233K | Buy |
47,527
+13,412
| +39% | +$65.8K | ﹤0.01% | 2872 |
|
|
2022
Q1 | $807K | Buy |
34,115
+2,408
| +8% | +$57K | ﹤0.01% | 2220 |
|
|
2021
Q4 | $561K | Buy |
31,707
+1,508
| +5% | +$26.7K | ﹤0.01% | 2463 |
|
|
2021
Q3 | $852K | Buy |
30,199
+7,724
| +34% | +$218K | ﹤0.01% | 2298 |
|
|
2021
Q2 | $236K | Buy |
22,475
+10,120
| +82% | +$106K | ﹤0.01% | 2876 |
|
|
2021
Q1 | $146K | Buy |
12,355
+490
| +4% | +$5.79K | ﹤0.01% | 2890 |
|
|
2020
Q4 | $139K | Buy |
11,865
+1,250
| +12% | +$14.6K | ﹤0.01% | 2915 |
|
|
2020
Q3 | $84K | Sell |
10,615
-2,110
| -17% | -$16.7K | ﹤0.01% | 2895 |
|
|
2020
Q2 | $233K | Buy |
+12,725
| New | +$233K | ﹤0.01% | 2697 |
|